Literature DB >> 33676554

METTL3-mediated m6A mRNA modification of FBXW7 suppresses lung adenocarcinoma.

Yingtong Wu1, Ning Chang2, Yong Zhang3, Xinxin Zhang3, Leidi Xu3, Yinggang Che3, Tianyun Qiao4, Bin Wu3, Ying Zhou3, Jun Jiang3, Jie Xiong3, Jian Zhang6, Jian Zhang6.   

Abstract

BACKGROUND: FBXW7 m6A modification plays an important role in lung adenocarcinoma (LUAD) progression; however, the underlying mechanisms remain unclear.
METHODS: The correlation between FBXW7 and various genes related to m6A modification was analyzed using The Cancer Genome Atlas database. The regulatory effects of METTL3 on FBXW7 mRNA m6A modification were examined in a cell model, and the underlying mechanism was determined by methylated RNA immunoprecipitation, RNA immunoprecipitation, luciferase reporter, and mutagenesis assays. In vitro experiments were performed to further explore the biological effects of METTL3-mediated FBXW7 m6A modification on LUAD development.
RESULTS: Decreased FBXW7 expression was accompanied by downregulated METTL3 expression in human LUAD tissues and was associated with a worse prognosis for LUAD in The Cancer Genome Atlas database. m6A was highly enriched in METTL3-mediated FBXW7 transcripts, and increased m6A modification in the coding sequence region increased its translation. Functionally, METTL3 overexpression or knockdown affected the apoptosis and proliferation phenotype of LUAD cells by regulating FBXW7 m6A modification and expression. Furthermore, FBXW7 overexpression in METTL3-depleted cells partially restored LUAD cell suppression in vitro and in vivo.
CONCLUSIONS: Our findings reveal that METTL3 positively regulates FBXW7 expression and confirm the tumor-suppressive role of m6A-modified FBXW7, thus providing insight into its epigenetic regulatory mechanisms in LUAD initiation and development.

Entities:  

Keywords:  Epigenetic modification; FBXW7; Lung adenocarcinoma; METTL3; m6A

Year:  2021        PMID: 33676554     DOI: 10.1186/s13046-021-01880-3

Source DB:  PubMed          Journal:  J Exp Clin Cancer Res        ISSN: 0392-9078


  46 in total

Review 1.  The prolyl isomerase PIN1: a pivotal new twist in phosphorylation signalling and disease.

Authors:  Kun Ping Lu; Xiao Zhen Zhou
Journal:  Nat Rev Mol Cell Biol       Date:  2007-11       Impact factor: 94.444

2.  p53-Altered FBXW7 expression determines poor prognosis in gastric cancer cases.

Authors:  Takehiko Yokobori; Koshi Mimori; Masaaki Iwatsuki; Hideshi Ishii; Ichiro Onoyama; Takeo Fukagawa; Hiroyuki Kuwano; Keiichi I Nakayama; Masaki Mori
Journal:  Cancer Res       Date:  2009-04-14       Impact factor: 12.701

3.  Tracing Oncogene Rearrangements in the Mutational History of Lung Adenocarcinoma.

Authors:  Jake June-Koo Lee; Seongyeol Park; Hansol Park; Sehui Kim; Jongkeun Lee; Junehawk Lee; Jeonghwan Youk; Kijong Yi; Yohan An; In Kyu Park; Chang Hyun Kang; Doo Hyun Chung; Tae Min Kim; Yoon Kyung Jeon; Dongwan Hong; Peter J Park; Young Seok Ju; Young Tae Kim
Journal:  Cell       Date:  2019-05-30       Impact factor: 41.582

Review 4.  Tumor suppression by the Fbw7 ubiquitin ligase: mechanisms and opportunities.

Authors:  Ryan J Davis; Markus Welcker; Bruce E Clurman
Journal:  Cancer Cell       Date:  2014-10-13       Impact factor: 31.743

Review 5.  Epitranscriptomics: regulation of mRNA metabolism through modifications.

Authors:  Eyal Peer; Gideon Rechavi; Dan Dominissini
Journal:  Curr Opin Chem Biol       Date:  2017-11-07       Impact factor: 8.822

Review 6.  Recent advances in SCF ubiquitin ligase complex: Clinical implications.

Authors:  Nana Zheng; Quansheng Zhou; Zhiwei Wang; Wenyi Wei
Journal:  Biochim Biophys Acta       Date:  2016-05-05

7.  Loss of Fbxw7 synergizes with activated Akt signaling to promote c-Myc dependent cholangiocarcinogenesis.

Authors:  Jingxiao Wang; Haichuan Wang; Michele Peters; Ning Ding; Silvia Ribback; Kirsten Utpatel; Antonio Cigliano; Frank Dombrowski; Meng Xu; Xinyan Chen; Xinhua Song; Li Che; Matthias Evert; Antonio Cossu; John Gordan; Yong Zeng; Xin Chen; Diego F Calvisi
Journal:  J Hepatol       Date:  2019-06-11       Impact factor: 25.083

8.  Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries.

Authors:  Freddie Bray; Jacques Ferlay; Isabelle Soerjomataram; Rebecca L Siegel; Lindsey A Torre; Ahmedin Jemal
Journal:  CA Cancer J Clin       Date:  2018-09-12       Impact factor: 508.702

9.  The TAL1 complex targets the FBXW7 tumor suppressor by activating miR-223 in human T cell acute lymphoblastic leukemia.

Authors:  Marc R Mansour; Takaomi Sanda; Lee N Lawton; Xiaoyu Li; Taras Kreslavsky; Carl D Novina; Marjorie Brand; Alejandro Gutierrez; Michelle A Kelliher; Catriona H M Jamieson; Harald von Boehmer; Richard A Young; A Thomas Look
Journal:  J Exp Med       Date:  2013-07-15       Impact factor: 14.307

Review 10.  The many faces of C/EBPδ and their relevance for inflammation and cancer.

Authors:  Kuppusamy Balamurugan; Esta Sterneck
Journal:  Int J Biol Sci       Date:  2013-09-20       Impact factor: 6.580

View more
  10 in total

1.  m6A mRNA methylation regulates the ERK/NF-κB/AKT signaling pathway through the PAPPA/IGFBP4 axis to promote proliferation and tumor formation in endometrial cancer.

Authors:  Peng Ruan; Shujun Wang; Chaoyi Yang; Xiaohui Huang; Pengxing Sun; Aili Tan
Journal:  Cell Biol Toxicol       Date:  2022-08-15       Impact factor: 6.819

Review 2.  Recent Insight on Regulations of FBXW7 and Its Role in Immunotherapy.

Authors:  Liangliang Xing; Leidi Xu; Yong Zhang; Yinggang Che; Min Wang; Yongxiang Shao; Dan Qiu; Honglian Yu; Feng Zhao; Jian Zhang
Journal:  Front Oncol       Date:  2022-06-24       Impact factor: 5.738

3.  m6A demethylase FTO promotes tumor progression via regulation of lipid metabolism in esophageal cancer.

Authors:  Xiaoran Duan; Li Yang; Liuya Wang; Qinghua Liu; Kai Zhang; Shasha Liu; Chaojun Liu; Qun Gao; Lifeng Li; Guohui Qin; Yi Zhang
Journal:  Cell Biosci       Date:  2022-05-14       Impact factor: 9.584

4.  ZNF677 suppresses renal cell carcinoma progression through N6-methyladenosine and transcriptional repression of CDKN3.

Authors:  Aolin Li; Congcong Cao; Ying Gan; Xiaofei Wang; Tianyu Wu; Quan Zhang; Yuchen Liu; Lin Yao; Qian Zhang
Journal:  Clin Transl Med       Date:  2022-06

5.  Comprehensive Analysis Revealed the Potential Implications of m6A Regulators in Lung Adenocarcinoma.

Authors:  Lingling Xie; Rongyang Dai; Xudong Wang; Guangfei Xie; Zhihua Gao; Xinxin Xu
Journal:  Front Mol Biosci       Date:  2022-03-28

Review 6.  Clinical significance of FBXW7 loss of function in human cancers.

Authors:  Jingyi Fan; Marcia Bellon; Mingyi Ju; Lin Zhao; Minjie Wei; Liwu Fu; Christophe Nicot
Journal:  Mol Cancer       Date:  2022-03-26       Impact factor: 27.401

Review 7.  The Emerging Role of N6-Methyladenosine RNA Methylation as Regulators in Cancer Therapy and Drug Resistance.

Authors:  Zhaolin Chen; Ying Hu; Le Jin; Fan Yang; Haiwen Ding; Lei Zhang; Lili Li; Tingting Pan
Journal:  Front Pharmacol       Date:  2022-04-06       Impact factor: 5.988

8.  ELAVL1 promotes prostate cancer progression by interacting with other m6A regulators.

Authors:  Zhonglin Cai; Huan Xu; Gang Bai; Hanjing Hu; Di Wang; Hongjun Li; Zhong Wang
Journal:  Front Oncol       Date:  2022-08-01       Impact factor: 5.738

Review 9.  The Role of m6A RNA Methylation in Cancer: Implication for Nature Products Anti-Cancer Research.

Authors:  Na Song; Kai Cui; Ke Zhang; Jie Yang; Jia Liu; Zhuang Miao; Feiyue Zhao; Hongjing Meng; Lu Chen; Chong Chen; Yushan Li; Minglong Shao; Jinghang Zhang; Haijun Wang
Journal:  Front Pharmacol       Date:  2022-06-16       Impact factor: 5.988

Review 10.  The molecular mechanism of METTL3 promoting the malignant progression of lung cancer.

Authors:  Chao Ma; Rui-Jie Ma; Kang Hu; Qi-Ming Zheng; Ye-Peng Wang; Nan Zhang; Zhi-Gang Sun
Journal:  Cancer Cell Int       Date:  2022-03-24       Impact factor: 5.722

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.